Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada

Medexus adds late-stage cell therapy to pipeline, but near-term value remains tethered to GRAFAPEX commercialization ramp

By The Northwire Desk — AI Analysis Jun 09, 2026 · 17:31 MDP · 4.03 MEDEXUS PHARMACEUTICALS INC. J
Executive Summary
  • Medexus Pharmaceuticals secured exclusive Canadian commercial rights to UM171 Cell Therapy (Zemcelpro®), a personalized hematopoietic stem cell transplantation product conditionally approved in Europe.
  • The transaction structure includes a $2 million initial payment to Cordex Biologics, quarterly royalties on net sales to ExCellThera, and various milestone payments. Medexus will sponsor the Health Canada New Drug Submission.
  • Zemcelpro® targets hematological malignancies requiring allo-HSCT. Phase 2 data (60 patients) demonstrated a 63.7% 24-month overall survival rate.
  • Commercialization in Canada is not expected before calendar year 2028, potentially 2031 depending on regulatory pathways.
  • The $2 million initial payment is funded entirely via the delayed draw term loan feature of Medexus's existing senior secured credit facility with National Bank of Canada.
  • Management states the deal is a strategic fit with existing hemato-oncology product treosulfan (GRAFAPEX) and will not significantly impact near-term capital allocation.
Material Impact
  • The UM171 license is a strategic pipeline add-on for the Canadian market, but commercialization is not expected until 2028. It does not change near-term revenue or cash flow profiles.
  • The stock's +40.6% run into this print implies the market has already priced in the GRAFAPEX ramp and credit facility success.
  • The news is Routine - Positive. It extends the franchise and validates management's hemato-oncology strategy, but lacks the immediacy or scale to re-rate the business. The market reaction will likely be muted, as the core value driver remains the GRAFAPEX commercial execution.
MDP · Price
Company Overview
  • Medexus Pharmaceuticals is a biopharmaceutical company focused on hemato-oncology and cell therapy.
  • Core product: GRAFAPEX (treosulfan) for injection, launched in the US in February 2025.
  • Pipeline: UM171 Cell Therapy (Zemcelpro®) licensed for Canada.
  • Financial profile: Transitioning from legacy generic erosion to new product commercialization. Strong balance sheet with low leverage and positive operating cash flow.
Read the original news release →

More from MEDEXUS PHARMACEUTICALS INC. J

Jun 25, 2026 · 18:01

GRAFAPEX execution on plan, but +44% run into print prices in the optimism; legacy erosion offsets top-line growth.

Earnings Apr 15, 2026 · 17:31

Medexus Confirms Cash Flow Accretion as GRAFAPEX Commercialization Accelerates

Production / Operations Feb 11, 2026 · 17:31

Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Earnings Nov 20, 2025 · 07:31

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Other Nov 17, 2025 · 18:35

Medexus obtains $51-million (U.S.) credit, plans NCIB

Financings Nov 17, 2025 · 08:31

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

Financings